French drug maker Sanofi SA, pressing forward with a global realignment, Monday notified about three dozen research and development employees in Massachusetts that their jobs will be eliminated, according to employees.
The jobs are in labs supporting the biosurgery, bone and joint disease, drug delivery discovery, and biomaterial engineering groups that were formerly part of Genzyme Corp., the employees said. Those labs are in Cambridge, Framingham, and Waltham.
Sanofi paid $20.1 billion to acquire Cambridge-based Genzyme in 2011 and has renamed the division Sanofi Genzyme. In a global restructuring that began last summer, Sanofi shifted oversight for research and development jobs in Massachusetts and elsewhere to a corporate research organization based in Paris.
A spokeswoman said Monday that she couldn’t immediately comment on the cuts. Sanofi told its labor unions earlier this month that it is paring about 600 jobs in France. The company has not confirmed cuts at other locations.
By Robert Weisman
Source: Boston Globe
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.
